441 related articles for article (PubMed ID: 24908435)
1. Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer.
Jiang Y; Mackley HB; Kimchi ET; Zhu J; Gusani N; Kaifi J; Staveley-O'Carroll KF; Belani CP
Cancer Chemother Pharmacol; 2014 Jul; 74(1):205-10. PubMed ID: 24908435
[TBL] [Abstract][Full Text] [Related]
2. Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
Starling N; Watkins D; Cunningham D; Thomas J; Webb J; Brown G; Thomas K; Oates J; Chau I
J Clin Oncol; 2009 Nov; 27(33):5499-505. PubMed ID: 19858399
[TBL] [Abstract][Full Text] [Related]
3. A phase I and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancer.
Roxburgh P; Lumsden GR; Paul J; Harden S; Sweeting L; James A; Crellin A; Morrison R; Evans TR; McDonald AC
Cancer Chemother Pharmacol; 2014 Jul; 74(1):131-9. PubMed ID: 24819683
[TBL] [Abstract][Full Text] [Related]
4. Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'.
Boeck S; Vehling-Kaiser U; Waldschmidt D; Kettner E; Märten A; Winkelmann C; Klein S; Kojouharoff G; Gauler T; Fischer von Weikersthal L; Clemens MR; Geissler M; Greten TF; Hegewisch-Becker S; Neugebauer S; Heinemann V
Anticancer Drugs; 2010 Jan; 21(1):94-100. PubMed ID: 19770635
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies.
Saif MW; Lansigan F; Ruta S; Lamb L; Mezes M; Elligers K; Grant N; Jiang ZL; Liu SH; Cheng YC
Phytomedicine; 2010 Mar; 17(3-4):161-9. PubMed ID: 20092990
[TBL] [Abstract][Full Text] [Related]
6. A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients.
Van Cutsem E; Verslype C; Beale P; Clarke S; Bugat R; Rakhit A; Fettner SH; Brennscheidt U; Feyereislova A; Delord JP
Ann Oncol; 2008 Feb; 19(2):332-9. PubMed ID: 17986625
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.
Duffy A; Kortmansky J; Schwartz GK; Capanu M; Puleio S; Minsky B; Saltz L; Kelsen DP; O'Reilly EM
Ann Oncol; 2008 Jan; 19(1):86-91. PubMed ID: 17878176
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study.
Francois E; Bennouna J; Chamorey E; Etienne-Grimaldi MC; Renée N; Senellart H; Michel C; Follana P; Mari V; Douillard JY; Milano G
Chemotherapy; 2012; 58(5):371-80. PubMed ID: 23235319
[TBL] [Abstract][Full Text] [Related]
9. Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.
Herman JM; Fan KY; Wild AT; Hacker-Prietz A; Wood LD; Blackford AL; Ellsworth S; Zheng L; Le DT; De Jesus-Acosta A; Hidalgo M; Donehower RC; Schulick RD; Edil BH; Choti MA; Hruban RH; Pawlik TM; Cameron JL; Laheru DA; Wolfgang CL
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):678-85. PubMed ID: 23773391
[TBL] [Abstract][Full Text] [Related]
10. Hypofractionated image-guided IMRT in advanced pancreatic cancer with simultaneous integrated boost to infiltrated vessels concomitant with capecitabine: a phase I study.
Passoni P; Reni M; Cattaneo GM; Slim N; Cereda S; Balzano G; Castoldi R; Longobardi B; Bettinardi V; Gianolli L; Gusmini S; Staudacher C; Calandrino R; Di Muzio N
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1000-6. PubMed ID: 24267968
[TBL] [Abstract][Full Text] [Related]
11. Definitive chemoradiation therapy with capecitabine in locally advanced pancreatic cancer.
Kim HS; Yi SY; Jun HJ; Lee J; Park SH; Lee JK; Lee KT; Lee KH; Choi DW; Choi SH; Heo JS; Park YS; Lim HY; Kang WK; Park HC; Lim DH; Park JO
Anticancer Drugs; 2010 Jan; 21(1):107-12. PubMed ID: 19829097
[TBL] [Abstract][Full Text] [Related]
12. A two-cohort phase I study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy for unresectable pancreatic carcinoma.
Raftery L; Tepper JE; Goldberg RM; Blackstock AW; Aklilu M; Bernard SA; Ivanova A; Davies JM; O'Neil BH
Am J Clin Oncol; 2013 Jun; 36(3):250-3. PubMed ID: 22547007
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of erlotinib plus capecitabine as first-line treatment for metastatic pancreatic cancer (XELTA study).
López R; Méndez CM; Fernández MJ; Reinoso CR; Aldana GQ; Fernández MS; DE LA Cámara Gómez J; López MR; Vázquez MR; Folgar SC
Anticancer Res; 2013 Feb; 33(2):717-23. PubMed ID: 23393373
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.
Mukherjee S; Hurt CN; Bridgewater J; Falk S; Cummins S; Wasan H; Crosby T; Jephcott C; Roy R; Radhakrishna G; McDonald A; Ray R; Joseph G; Staffurth J; Abrams RA; Griffiths G; Maughan T
Lancet Oncol; 2013 Apr; 14(4):317-26. PubMed ID: 23474363
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of limited field radiotherapy with concurrent capecitabine in locally advanced pancreatic cancer.
Jackson AS; Jain P; Watkins GR; Whitfield GA; Green MM; Valle J; Taylor MB; Dickinson C; Price PM; Saleem A
Clin Oncol (R Coll Radiol); 2010 Sep; 22(7):570-7. PubMed ID: 20650619
[TBL] [Abstract][Full Text] [Related]
16. Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study.
Iannitti D; Dipetrillo T; Akerman P; Barnett JM; Maia-Acuna C; Cruff D; Miner T; Martel D; Cioffi W; Remis M; Kennedy T; Safran H
Am J Clin Oncol; 2005 Dec; 28(6):570-5. PubMed ID: 16317266
[TBL] [Abstract][Full Text] [Related]
17. The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.
Watkins DJ; Starling N; Cunningham D; Thomas J; Webb J; Brown G; Barbachano Y; Oates J; Chau I
Eur J Cancer; 2014 May; 50(8):1422-9. PubMed ID: 24613126
[TBL] [Abstract][Full Text] [Related]
18. Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer.
Chadha AS; Skinner HD; Gunther JR; Munsell MF; Das P; Minsky BD; Delclos ME; Chatterjee D; Wang H; Clemons M; George G; Singh PK; Katz MH; Fleming JB; Javle MM; Wolff RA; Varadhachary GR; Crane CH; Krishnan S
PLoS One; 2016; 11(6):e0156910. PubMed ID: 27336466
[TBL] [Abstract][Full Text] [Related]
19. Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial.
Das P; Eng C; Rodriguez-Bigas MA; Chang GJ; Skibber JM; You YN; Maru DM; Munsell MF; Clemons MV; Kopetz SE; Garrett CR; Shureiqi I; Delclos ME; Krishnan S; Crane CH
Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):301-5. PubMed ID: 24315563
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer.
Kordes S; Klümpen HJ; Weterman MJ; Schellens JH; Richel DJ; Wilmink JW
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1135-41. PubMed ID: 25822310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
